July/August 2007

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther in pursuit of knowledge and new discoveries. In this issue we highlight presentations from the 43rd annual ASCO meeting as well as research being done at Massachusetts General Hospital and Dana-Farber Cancer Institute in Boston and the University of Texas Southwestern Medical Center in Dallas.

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) GlaxoSmithKline 2) Ventana Medical Systems Inc. and Roche Holding AG, and more

Among the articles provided in this issue are topics presented at the 43rd annual meeting of the American Society of Clinical Oncology.

Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more

In this issue we highlight topics presented at the 43rd annual meeting of the American Society of Clinical Oncology: 1) Focus Groups and Advisory Boards: To What Extent Do They Supplement Oncologists' Income? 2) The High Overhead Cost of Complying With National Guidelines, and more

According to the U.S. National Cancer Institute, there are 19,000 new cases of primary brain cancer diagnosed each year. The five-year survival rate is around 30%. Brain cancers can strike all ages, and are the leading cause of cancer deaths in children under the age of 20.

At ASCO's 43rd annual meeting in Chicago, more than 4,000 abstracts were presented, and 25,000 specialists from around the world convened to hear the latest advances in cancer treatment.

This issue of Oncology & Biotech News presents some of the most noteworthy and newsworthy information from the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.